balanc gener landscap lead improv outlook key take-away
cah call today gener environ improv origin
expect cah balanc purchas vs sell drive out-performance
inflect gener deflationari trend experienc continu
persist turn benefit red oak sourc partner
all-in help turn around cah gener program
headwind tailwind within specialti rx distribut manag note
growth continu come volum new specialti launch
expans indic exist product also call keytruda key
drug drive growth within specialti similar peer posit revis pharma
segment ebit growth also includ absorpt mln addit opioid expens
relat propos global settlement all-in opioid expens expect
mln mln ramp expens relat
opioid still remain earli manag perspect settlement
medic segment compani take conserv stanc segment
surround gown recal initi jan lower volum brand
product could volatil move forward relat recal
commerci effort compani take proactiv step address issu
servic level could mitig impact compani
rais estim pt back today result rais ep
see improv profit growth within pharma segment
rel prior view believ specialti continu driver
despit smaller footprint rel peer medic remain wild card believ
manag view may quit conserv back half given significantli
easier comp rais ep expect cost
save materi benefit specialty/gener program persist
rais pt base price-to-earnings ep
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
idc link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight equal weight
compani continu face headwind core
pharma distribut busi well medcial
busi addit on-going opioid trial
continu weigh compani
upsid case see multipl expand proof
point begin emerg compani cost
cut initi yield benefit grow ebit
downsid case see wors expect opioid
settlement continu weak pharma
medic segment
segmentrevenu growthmsd growthmsd growthmsd growthprofit ebit growthhsd ldd declinehsd ldd declinelsd declinegener pricingbrand pricingsimilar msd similar msd similar msd medic segmentrev growthlsd growthlsd growthlsd growthebit growthldd growthldd growthldd growthnon-gaap effect tax expens dilut mlncapit mln mln mln earn seq barclay cardin
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
unless otherwis indic price sourc bloomberg reflect close price relev trade market may
last avail price time public
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay plc director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
fd barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
south korean regul
gd one research analyst fundament credit coverag team member household long posit
common equiti secur issuer
ge one research analyst fundament equiti coverag team member household long posit
common equiti secur issuer
 issuer benefici own class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement issuer provis financi servic barclay bank plc and/or
affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or relat
